Immunexpress, Inc., a Seattle, WA-based medical diagnostic company focused on improving outcomes for suspected sepsis patients, closed a major private funding round.
The amount of the deal and the backers were not disclosed.
The company intends to use the funds to achieve its immediate corporate goal, the 510(k) clearance of SeptiCyte™ RAPID from the U.S. Food and Drug Administration (FDA) and, secondly, support the commercial launch of the assay.
Led by Rolland D. Carlson, Ph.D., Chief Executive Officer, Immunexpress is a molecular diagnostic company committed to improving outcomes for patients suspected of sepsis. Its SeptiCyte™ technology quantifies, directly from whole blood, specific molecular markers from the patient’s own immune system – the “host response.”